Correlation of mRNA-PCA3 urine levels with the new grading system in prostate cancer.

To evaluate the PCA3 (Prostate Cancer 3 gene) as a tool to improve prostate cancer (PCa) screening and its capability to predict PCa aggressiveness.

A retrospective study with data from consecutive patients with suspected PCa seen in the urology department between November 2009 and April 2016 and who were candidates for prostate biopsy. A total of 1038 urine samples were tested in our laboratory with a kit that generated a PCA3 score (s-PCA3). A prostate biopsy was recommended only in those patients with s-PCA3≥35. Associations between variables were analyzed using the R software.

In patients with a positive s-PCA3 (44.5%), a subsequent biopsy was recommended. Of a total of 151 biopsies studied, 56.3% yielded a diagnosis of PCa. The probability of a positive biopsy increased as the s-PCA3 increased (p=0.041). The percentage of affected cylinders increased as the s-PCA3 increased (p=0.015). A statistically significant relationship was observed between s-PCA3 and both the Gleason score and the Grade Group (p=0.001 and 0.008, respectively). The best log-linear models and a logistic model confirmed the relationships shown previously with Fisher's exact tests.

S-PCA3 may serve as an additional marker to reduce the indication for biopsies and avoid overdiagnosis and overtreatment of patients with suspected PCa. The prognostic significance of s-PCA3 was confirmed, as it was associated with tumor volume and Gleason score. Importantly, to our knowledge this is the first time that an association has been demonstrated between s-PCA3 and the new Grade Group.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia. 2018 Jun 18 [Epub]

Natalia Rodon, Isabel Trias, Montse Verdú, Miquel Calvo, Josep Mª Banus, Xavier Puig

BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain. Electronic address: ., BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain; HISTOPAT Laboratoris, Barcelona, Spain; Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona, Spain., BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain; HISTOPAT Laboratoris, Barcelona, Spain., Department of Statistics, Faculty of Biology, Universitat de Barcelona, Barcelona, Spain., ICUN, Institut Català d'Urologia i Nefrologia, Barcelona, Spain.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe